↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Bristol Myers Squibb$BMY · filed: saw revenue fall 0.2% in FY2025 to $48.2BNew shipTrillion Score 505Fall Risk LowNext year $43.5B–$50.6B sealedCheck ▾Close ▴
What Bristol Myers Squibb filed
Saw revenue fall 0.2% in FY2025 to $48.2 billion, equity 20.5% of assets, and dividend per share up 18 years running. Every figure links to the filing it came from on Bristol Myers Squibb’s card. New ship: no warning signs. Trillion Score 505, #89 of 182 in its field; Fall Risk Low (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $43.5B and $50.6B, an 80% range sealed on 26 Sept 2026 · receipt #1b40a0 · graded in public by the revenue in Bristol Myers Squibb’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Bristol funds dividend raises through margin expansion, not pipeline wins—**$4.8B** in productivity savings buys four years of runway.
$4.8 billion
in cumulative productivity savings by 2028
$0.62
per share quarterly
4.7%
against a share price near
$53
Free cash flow over the trailing twelve months reached
Bristol Myers Squibb marked its eighteenth consecutive annual dividend increase this week, a run built less on blockbuster approvals and more on the quiet arithmetic of cost discipline. The company targets $4.8 billion in cumulative productivity savings by 2028, a figure that now underwrites dividend policy as patent cliffs loom on Revlimid and Opdivo.
The dividend itself rose 2.1% to $0.62 per share quarterly, or $2.48 annualized, bringing the current yield to 4.7% against a share price near $53. Free cash flow over the trailing twelve months reached $9.1 billion, covering the $6.2 billion annual dividend outlay with a payout ratio of 68%—not tight, but no longer the expansive cushion of 2018 when Celgene's integration promised revenue synergies that never fully materialized. Management now funds raises through margin, not revenue momentum.
The productivity program strips $1.5 billion in annual run-rate costs by end-2025, targeting procurement rationalization, site consolidation, and headcount optimization across commercial and G&A functions. Bristol closed 12 manufacturing facilities since 2022 and reduced global workforce by 8% without touching R&D spend, which held at 24% of revenue through the restructuring. The savings flow directly to operating margin, which expanded 180 basis points year-over-year to 28.3% in the latest quarter, even as Revlimid sales declined 34% and Opdivo growth stalled at 3%. This is dividend funding by attrition, not innovation—acceptable when the base business throws off $22 billion in annual revenue and the pipeline remains adequately stocked, if not spectacular.
Allocators care because this is the pharma majors' new playbook: defend the dividend through efficiency when exclusivity windows close and biosimilar pressure mounts. Bristol's streak matters less as a badge and more as a signal that large-cap pharma can maintain capital return commitments without the mega-merger synergies Wall Street chased in the 2010s. The model works if productivity gains stay ahead of revenue erosion—Bristol's $4.8 billion target buys roughly four years of dividend cushion at current payout levels, assuming no top-line growth. After that, the late-stage pipeline must deliver, or the streak ends.
Watch for the Q4 2025 earnings call, when management updates progress on the $1.5 billion near-term savings milestone and provides 2026 margin guidance. If operating margin holds above 28% into next year despite Revlimid's continued decline, the dividend remains safe through 2027. Also track FDA action on three Phase III assets—schizophrenia candidate KarXT, LAG-3 combo in melanoma, and next-gen CAR-T in multiple myeloma—all expected to read out by mid-2026. These determine whether Bristol can eventually grow into its dividend again, or simply defend it.
The streak continues not because Bristol discovered anything, but because it stopped pretending it needed to.
Branded by POPS4 · proof in 60 seconds
For the principal
Bristol's dividend model is now cost-discipline, not growth—acceptable for income allocation if you believe pharma majors can manage decline.
For the operator
Track Q4 margin guidance closely; 28% operating margin is the threshold that confirms the productivity story funds capital return through 2027.
For the house
Maintain neutral weight; dividend safe near-term but multiple expansion unlikely without pipeline execution—better income opportunities in medtech with growth.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
